Reports
Sale
Global Cell and Gene Therapy Market Size, Share, Trends, Overview: By Type: Cell Therapy Types, Gene Therapy Types; By Indications: Oncology, Cardiology, CNS, Musculoskeletal, Infectious Diseases, Dermatology, Endocrine, Metabolic, Genetic, Others; By Product Type; By End User; Regional Analysis; Supplier Landscape; 2024-2032
Cell and Gene Therapy Market Outlook:
The cell and gene therapy market size was valued at USD 17.4 billion in 2023, driven by the increasing prevalence of chronic disorders like cancer across the globe. The market size is anticipated to grow at a CAGR of 23.17% during the forecast period of 2024-2032 to achieve a value of USD 113.53 billion by 2032.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Cell and Gene Therapy: Introduction
Cell therapy works on the principle of alteration, implantation, or restoration of cells or by extrapolating cells to carry the treatment through the body. In cell therapy, cells are modified outside the body, that is, in ex-vivo conditions, and then injected into the patient. On the other hand, gene therapy works by incorporating, deactivating, or displacing the genes into cells, which can occur both inside (in vivo) and outside (ex vivo) of the body.
In the healthcare sector, some of the major treatments and curative remedies are developed using cell and gene modifications. Cell and gene therapy works by modifying the genes in particular cells and injecting them into the body. The essential resemblance between cell and gene therapy is the ability to mitigate the underlying cause of genetic disorders. There are enormous cell and gene therapies based on the origin or destination as per the treatment requirements.
Cell and Gene Therapy Market Analysis
The emerging cell and gene therapies seem promising in commercial aspects. Key market leaders will be the gene therapy companies that will provide fast and effective treatment for debilitating diseases. Gene therapies developed by small, medium, and big biotech and pharmaceutical companies also tend to attract the attention of investors. According to the Food and Drug Administration’s anticipation, by 2025, 10 to 20 new cell and gene therapies are anticipated to be approved.
The U.S. Food and Drug Administration has recently given its approval for the first gene therapy called Elevidys. It is intended for the treatment of pediatric patients aged 4 through 5 years who are suffering from Duchenne muscular dystrophy (DMD) and have confirmed mutations in the DMD gene. This therapy can be used for patients who do not have any pre-existing medical conditions that prevent treatment with this therapy. Such approvals are anticipated to contribute significantly to the cell and gene therapy market share. Along with Elevidys, the U.S. FDA has given approval to a total of 6 cell and gene therapies including Vyjuvek, ARCT-154, and Qalsody among other therapies. Advanced technologies and better healthcare infrastructure facilities are the additional factors helping in the development of this market.
Based on regions, North America is expected to dominate the market due to the presence of key market players in the region. The United States of America has witnessed a substantial increase in biopharmaceutical companies performing clinical trials in cell and gene therapy. It has been made clear by several reports that more than 1000 companies worldwide have been working on the development of cell and gene therapies, out of which more than 500 companies are based in the United States.
Cell and Gene Therapy Market Segmentations
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Market Breakup by Type
- Cell Therapy Types
- Autologous Cell Therapy
- Autogenic Cell Therapy
- Ex-vivo Cell Therapy
- In-vivo Cell Therapy
- Gene Therapy Types
- Somatic Cell Gene Therapy
- Germline Gene Therapy
- Ex-vivo Gene Therapy
- In-vivo Gene Therapy
Market Breakup by Indications
- Oncology
- Cardiology
- CNS
- Musculoskeletal
- Infectious Diseases
- Dermatology
- Endocrine, Metabolic, Genetic
- Immunology and Inflammation
- Ophthalmology
- Hematology
- Gastroenterology
- Others
Market Breakup by Product Type
- Yescarta
- Provenge
- Luxtura
- Kymriah
- Imlygic
- Gintuit
- MACI
- Laviv
- Gendicine
- Oncorine
- Neovasculgen
- Strimvelis
- Invossa
- Zolgenesma
- Tecartus
- Lisocel
- Zyntelego
- Others
Market Breakup by End User
- Hospitals
- Ambulatory Surgical Centres
- Wound Care Centres
- Cancer Care Centres
- Others
Market Breakup by Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Cell and Gene Therapy Market Overview
The increase in the prevalence of chronic disorders, like cancer, is responsible for driving the growth of this market. The increased expenditure in the research and development sector and enhanced government support are also expected to propel the cell and gene therapy market demand during the forecast period.
Over the last decade, cell and gene therapy has accelerated and resulted in multiple effective treatments for various indications. These novel therapies and strategies have grabbed the attention of the entire biotech and pharma industry and are visible as future hallmarks of the cell and gene therapy market. The field of cell and gene therapy is still young compared to other modalities which further anticipates the cell and gene therapy market growth in the forecast period.
A collaborative industry effort has focused on applying chimeric anti-receptor T-cells for oncology indications. The incorporation of cell and gene therapy in hematopoietic stem cells has increased hopes for new therapeutic strategies and better treatment solutions, including hematological, neurological, and ocular symptoms. This collaborative effort has significantly bolstered the market growth.
Cell and Gene Therapy Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- Amgen, Inc.
- Bluebird Bio, Inc.
- Castle Creek Pharmaceutical Holdings
- Kite Pharma, Inc.
- Novartis AG
- Orchard Therapeutics plc.
- Pfizer, Inc.
- Spark Therapeutics, Inc.
- Vericel Corporation
- Precision BioSciences
- Kolon Tissuegene Inc.
- Takeda Pharmaceutical Company
- Vertex Pharmaceuticals Inc.
- Sangamo Therapeutics Inc.
- Organogenesis Holdings Inc.
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
|---|---|
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Type |
|
| Breakup by Indications |
|
| Breakup by Product Type |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global Cell and Gene Therapy Market Overview
3.1 Global Cell and Gene Therapy Market Historical Value (2017-2023)
3.2 Global Cell and Gene Therapy Market Forecast Value (2024-2032)
4 Global Cell and Gene Therapy Market Landscape
4.1 Global Cell and Gene Therapy Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Global Cell and Gene Therapy Product Landscape
4.2.1 Analysis by Type
4.2.2 Analysis by Indications
5 Global Cell and Gene Therapy Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.3 Porter’s Five Forces Model
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Global Cell and Gene Therapy Market Segmentation
6.1 Global Cell and Gene Therapy Market by Type
6.1.1 Market Overview
6.1.2 Cell Therapy Types
6.1.2.1 Autologous Cell Therapy
6.1.2.2 Autogenic Cell Therapy
6.1.2.3 Ex-vivo Cell Therapy
6.1.2.4 In-vivo Cell Therapy
6.1.3 Gene Therapy Types
6.1.3.1 Somatic Cell Gene Therapy
6.1.3.2 Germline Gene Therapy
6.1.3.3 Ex-vivo Gene Therapy
6.1.3.4 In-vivo Gene Therapy
6.2 Global Cell and Gene Therapy Market by Indications
6.2.1 Market Overview
6.2.2 Oncology
6.2.3 Cardiology
6.2.4 CNS
6.2.5 Musculoskeletal
6.2.6 Infectious Diseases
6.2.7 Dermatology
6.2.8 Endocrine, Metabolic, Genetic
6.2.9 Immunology and Inflammation
6.2.10 Ophthalmology
6.2.11 Hematology
6.2.12 Gastroenterology
6.2.13 Others
6.3 Global Cell and Gene Therapy Market by Product Type
6.3.1 Market Overview
6.3.2 Yescarta
6.3.3 Provenge
6.3.4 Luxtura
6.3.5 Kymriah
6.3.6 Imlygic
6.3.7 Gintuit
6.3.8 MACI
6.3.9 Laviv
6.3.10 Gendicine
6.3.11 Oncorine
6.3.12 Neovasculgen
6.3.13 Strimvelis
6.3.14 Invossa
6.3.15 Zolgenesma
6.3.16 Tecartus
6.3.17 Lisocel
6.3.18 Zyntelego
6.3.19 Others
6.4 Global Cell and Gene Therapy Market by End User
6.4.1 Market Overview
6.4.2 Hospitals
6.4.3 Ambulatory Surgical Centres
6.4.4 Wound Care Centres
6.4.5 Cancer Care Centres
6.4.6 Others
6.5 Global Cell and Gene Therapy Market by Region
6.5.1 Market Overview
6.5.2 North America
6.5.3 Europe
6.5.4 Asia Pacific
6.5.5 Latin America
6.5.6 Middle East and Africa
7 North America Cell and Gene Therapy Market
7.1 Market Share by Country
7.2 United States of America
7.3 Canada
8 Europe Cell and Gene Therapy Market
8.1 Market Share by Country
8.2 United Kingdom
8.3 Germany
8.4 France
8.5 Italy
8.6 Others
9 Asia Pacific Cell and Gene Therapy Market
9.1 Market Share by Country
9.2 China
9.3 Japan
9.4 India
9.5 ASEAN
9.6 Australia
9.7 Others
10 Latin America Cell and Gene Therapy Market
10.1 Market Share by Country
10.2 Brazil
10.3 Argentina
10.4 Mexico
10.5 Others
11 Middle East and Africa Cell and Gene Therapy Market
11.1 Market Share by Country
11.2 Saudi Arabia
11.3 United Arab Emirates
11.4 Nigeria
11.5 South Africa
11.6 Others
12 Patent Analysis
12.1 Analysis by Type of Patent
12.2 Analysis by Publication year
12.3 Analysis by Issuing Authority
12.4 Analysis by Patent Age
12.5 Analysis by CPC Analysis
12.6 Analysis by Patent Valuation
12.7 Analysis by Key Players
13 Grants Analysis
13.1 Analysis by year
13.2 Analysis by Amount Awarded
13.3 Analysis by Issuing Authority
13.4 Analysis by Grant Application
13.5 Analysis by Funding Institute
13.6 Analysis by NIH Departments
13.7 Analysis by Recipient Organization
14 Clinical Trials Analysis
14.1 Analysis by Trial Registration Year
14.2 Analysis by Trial Status
14.3 Analysis by Trial Phase
14.4 Analysis by Therapeutic Area
14.5 Analysis by Geography
15 Funding and Investment Analysis
15.1 Analysis by Funding Instances
15.2 Analysis by Type of Funding
15.3 Analysis by Funding Amount
15.4 Analysis by Leading Players
15.5 Analysis by Leading Investors
15.6 Analysis by Geography
16 Partnership and Collaborations Analysis
16.1 Analysis by Partnership Instances
16.2 Analysis by Type of Partnership
16.3 Analysis by Leading Players
16.4 Analysis by Geography
17 Regulatory Framework
17.1 Regulatory Overview
17.1.1 US FDA
17.1.2 EU EMA
17.1.3 INDIA CDSCO
17.1.4 JAPAN PMDA
17.1.5 Others
18 Supplier Landscape
18.1 Amgen, Inc.
18.1.1 Financial Analysis
18.1.2 Product Portfolio
18.1.3 Demographic Reach and Achievements
18.1.4 Mergers and Acquisitions
18.1.5 Certifications
18.2 Bluebird Bio, Inc.
18.2.1 Financial Analysis
18.2.2 Product Portfolio
18.2.3 Demographic Reach and Achievements
18.2.4 Mergers and Acquisitions
18.2.5 Certifications
18.3 Castle Creek Pharmaceutical Holdings
18.3.1 Financial Analysis
18.3.2 Product Portfolio
18.3.3 Demographic Reach and Achievements
18.3.4 Mergers and Acquisitions
18.3.5 Certifications
18.4 Kite Pharma, Inc.
18.4.1 Financial Analysis
18.4.2 Product Portfolio
18.4.3 Demographic Reach and Achievements
18.4.4 Mergers and Acquisitions
18.4.5 Certifications
18.5 Novartis AG
18.5.1 Financial Analysis
18.5.2 Product Portfolio
18.5.3 Demographic Reach and Achievements
18.5.4 Mergers and Acquisitions
18.5.5 Certifications
18.6 Orchard Therapeutics plc.
18.6.1 Financial Analysis
18.6.2 Product Portfolio
18.6.3 Demographic Reach and Achievements
18.6.4 Mergers and Acquisitions
18.6.5 Certifications
18.7 Pfizer, Inc.
18.7.1 Financial Analysis
18.7.2 Product Portfolio
18.7.3 Demographic Reach and Achievements
18.7.4 Mergers and Acquisitions
18.7.5 Certifications
18.8 Spark Therapeutics, Inc.
18.8.1 Financial Analysis
18.8.2 Product Portfolio
18.8.3 Demographic Reach and Achievements
18.8.4 Mergers and Acquisitions
18.8.5 Certifications
18.9 Vericel Corporation Inc.
18.9.1 Financial Analysis
18.9.2 Product Portfolio
18.9.3 Demographic Reach and Achievements
18.9.4 Mergers and Acquisitions
18.9.5 Certifications
18.10 Precision BioSciences
18.10.1 Financial Analysis
18.10.2 Product Portfolio
18.10.3 Demographic Reach and Achievements
18.10.4 Mergers and Acquisitions
18.10.5 Certifications
18.11 Kolon Tissuegene Inc.
18.11.1 Financial Analysis
18.11.2 Product Portfolio
18.11.3 Demographic Reach and Achievements
18.11.4 Mergers and Acquisitions
18.11.5 Certifications
18.12 Takeda Pharmaceutical Company
18.12.1 Financial Analysis
18.12.2 Product Portfolio
18.12.3 Demographic Reach and Achievements
18.12.4 Mergers and Acquisitions
18.12.5 Certifications
18.13 Vertex Pharmaceuticals Inc.
18.13.1 Financial Analysis
18.13.2 Product Portfolio
18.13.3 Demographic Reach and Achievements
18.13.4 Mergers and Acquisitions
18.13.5 Certifications
18.14 Sangamo Therapeutics Inc.
18.14.1 Financial Analysis
18.14.2 Product Portfolio
18.14.3 Demographic Reach and Achievements
18.14.4 Mergers and Acquisitions
18.14.5 Certifications
18.15 Organogenesis Holdings Inc.
18.15.1 Financial Analysis
18.15.2 Product Portfolio
18.15.3 Demographic Reach and Achievements
18.15.4 Mergers and Acquisitions
18.15.5 Certifications
19 Global Cell and Gene Therapy Market - Distribution Model (Additional Insight)
19.1 Overview
19.2 Potential Distributors
19.3 Key Parameters for Distribution Partner Assessment
20 Key Opinion Leaders (KOL) Insights (Additional Insight)
21 Company Competitiveness Analysis (Additional Insight)
21.1 Very Small Companies
21.2 Small Companies
21.3 Mid-Sized Companies
21.4 Large Companies
21.5 Very Large Companies
22 Payment Methods (Additional Insight)
22.1 Government Funded
22.2 Private Insurance
22.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
Key Questions Answered in the Report
The market attained a value of about USD 17.4 billion in 2023, driven by the increased drug approvals.
The market is anticipated to grow at a CAGR of 23.17% during the forecast period of 2024-2032 and is likely to reach a market value of USD 113.53 billion by 2032.
The market is driven by the increased prevalence of chronic diseases such as cancer worldwide, along with the rapidly developing healthcare scetor.
The increasing number of FDA approvals for new gene and cell therapies is a major trend influencing the market growth.
The major regions of the market include North America, Europe, Asia Pacific, Latin America, Middle East and Africa. North America is currently leading the global market.
Cell therapies can be divided into autologous cell therapy, autogenic cell therapy, ex-vivo cell therapy, and in-vivo cell therapy. Gene therapies can be categorized into somatic cell gene therapy, germline gene therapy, ex-vivo gene therapy, and in-vivo gene therapy.
Indications that use this therapy include oncology, cardiology, CNS, musculoskeletal, infectious diseases, dermatology, endocrine, metabolic, genetic, immunology and inflammation, ophthalmology, hematology, and gastroenterology, among others.
Different products in the market include Yescarta, Provenge, Luxtura, Kymriah, Imlygic, Gintuit, MACI, Laviv, Gendicine, Oncorine, Neovasculgen, Strimvelis, Invossa, Zolgenesma, Tecartus, Lisocel, and Zyntelego, among others.
End users include hospitals, ambulatory surgical centres, wound care centres, and cancer care centres, among others.
Key players involved in the market are Amgen, Inc., Bluebird Bio, Inc., Castle Creek Pharmaceutical Holdings, Kite Pharma, Inc., Novartis AG, Orchard Therapeutics plc., Pfizer, Inc., Spark Therapeutics, Inc., Vericel Corporation, Precision BioSciences, Kolon Tissuegene Inc., Organogenesis Holdings Inc., Vertex Pharmaceuticals Inc., Sangamo Therapeutics Inc., and Takeda Pharmaceutical Company.
Purchase Options
Call us on
Purchase Full Report
Mini Report
$ 3499
$1999
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 5999
$2999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 7999
$3999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 9999
$5999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER